ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Kidney-Specific Immunosuppression without Adverse Systemic Effects.

D. Kentrup,1 K. Schuette-Nuetgen,1 H. Pawelski,1 H. Pavenstädt,1 S. Hermann,2 M. Schaefers,2 G. Larbig,3 A. Kuebelbeck,3 S. Reuter.1

1Department of Medicine D, University Hospital Muenster, Muenster, Germany
2European Institute for Molecular Imaging - EIMI, University Hospital Muenster, Muenster, Germany
3Merck KGaA, Darmstadt, Germany

Meeting: 2017 American Transplant Congress

Abstract number: A136

Keywords: Glucocortocoids, Immunosuppression, Kidney transplantation, Rejection

Session Information

Session Name: Poster Session A: Immunosuppression

Session Type: Poster Session

Date: Saturday, April 29, 2017

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall D1

Purpose: Immunosuppressive therapy is often accompanied by severe adverse effects. To overcome this, the aim of this study was the evaluation of a kidney-specific drug delivery mechanism in a rat model of allogeneic kidney transplantation: Coupling prednisolone to a polypeptide enables organ specific immunosuppression, avoiding adverse systemic effects.

Methods: Ten groups of animals were used for the experiments (N=5-6): syngeneically (Lewis Brown Norway F1 to Lewis Brown Norway F1) and allogeneically (Lewis Brown Norway F1 to Lewis) transplanted rats without immunosuppressive therapy, as well as allogeneically transplanted animals receiving either conventional or kidney-specific prednisolone at two different concentrations (4mg/kg/12h or 16mg/kg/12h, i.p). Immunosuppressive treatment was either preventive (continuous treatment until the end of the experiment 4 days post surgery; six groups) or therapeutic (started 4 days after surgery and maintained for 3 days until day 7 post surgery; 4 groups, no low dose treatment). Treatment efficiency was evaluated 4 days post surgery by 18F-FDG positron emission tomography in the preventive experimental setting, or on day 4 (baseline), day 5 and day 7 post surgery in the therapeutic setting. Histological analyses were performed at the end of the experiments and blood glucose levels were measured to assess possible systemic effects.

Results: Conventional prednisolone in high dosage significantly reduced renal 18F-FDG accumulation and histological signs of rejection in the preventive and the therapeutic setting. Conventional low dose treatment had no effect. Animals treated with kidney-specific prednisolone showed significant amelioration of graft rejection already at low dose treatment in the preventive experimental setting, high dose treatment was at least as effective as conventional treatment in both the preventive and therapeutic setting. Elevated blood glucose levels were only observed after administration of conventional prednisolone.

Conclusions: Kidney-specific prednisolone proved to be effective in the prevention and therapy of renal acute cellular graft rejection and may even outperform conventional prednisolone. Organ-specific immunosuppression is, at least in the case of renal transplants, possible.

CITATION INFORMATION: Kentrup D, Schuette-Nuetgen K, Pawelski H, Pavenstädt H, Hermann S, Schaefers M, Larbig G, Kuebelbeck A, Reuter S. Kidney-Specific Immunosuppression without Adverse Systemic Effects. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kentrup D, Schuette-Nuetgen K, Pawelski H, Pavenstädt H, Hermann S, Schaefers M, Larbig G, Kuebelbeck A, Reuter S. Kidney-Specific Immunosuppression without Adverse Systemic Effects. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/kidney-specific-immunosuppression-without-adverse-systemic-effects/. Accessed May 12, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences